AMG 305 - Amgen
"Next up at #AACR23 New Drugs on the Horizon pt 2, Amgen discloses AMG305, a bispecific BiTE targeting CDH3 and MSLN." (@KRHornberger) Apr 16, 2023 
Oncology • CDH3 • MSLN
https://twitter.com/KRHornberger/status/1647686965473443840
 
Apr 16, 2023
 
 
d91cfc62-3e9d-49a2-9e94-54471e3a83e5.jpg

6467a112-b8d0-4949-bb78-651ef1501c3b.jpg

7cb60ccd-cd22-4f4d-8c75-5040bad93c3d.jpg

83c83d69-a31d-434a-9cf4-ae876eca772c.jpg